Early Administration of IL-6RA Does Not Prevent Radiation-induced Lung Injury in Mice

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2010 Apr 9

PMID 20374625

Citations 7

Authors

Toshiyuki Ogata

Hideya Yamazaki

Teruki Teshima

Ayaka Kihara

Yuko Suzumoto

Takehiro Inoue

Norihiro Nishimoto

Nariaki Matsuura

Affiliations

Soon will be listed here.

Abstract

Background: Radiation pneumonia and subsequent radiation lung fibrosis are major dose-limiting complications for patients undergoing thoracic radiotherapy. Interleukin-6 (IL-6) is a pleiotropic cytokine and plays important roles in the regulation of immune response and inflammation. The purpose of this study was to investigate whether anti-IL-6 monoclonal receptor antibody (IL-6RA) could ameliorate radiation-induced lung injury in mice.

Methods: BALB/cAnNCrj mice having received thoracic irradiation of 21 Gy were injected intraperitoneally with IL-6RA (MR16-1) or control rat IgG twice, immediately and seven days after irradiation. Enzyme-linked immunosorbent assay was used to examine the plasma level of IL-6 and serum amyloid A (SAA). Lung injury was assessed by histological staining with haematoxylin and eosin or Azan, measuring lung weight, and hydroxyproline.

Results: The mice treated with IL-6RA did not survive significantly longer than the rat IgG control. We observed marked up-regulation of IL-6 in mice treated with IL-6RA 150 days after irradiation, whereas IL-6RA temporarily suppressed early radiation-induced increase in the IL-6 release level. Histopathologic assessment showed no differences in lung section or lung weight between mice treated with IL-6RA and control.

Conclusions: Our findings suggest that early treatment with IL-6RA after irradiation alone does not protect against radiation-induced lung injury.

Citing Articles

Cytokines and radiation-induced pulmonary injuries.

Lierova A, Jelicova M, Nemcova M, Proksova M, Pejchal J, Zarybnicka L J Radiat Res. 2018; 59(6):709-753.

PMID: 30169853 PMC: 6251431. DOI: 10.1093/jrr/rry067.

Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism.

Patin F, Baranek T, Vourch P, Nadal-Desbarats L, Goossens J, Marouillat S Neurotherapeutics. 2016; 13(4):905-917.

PMID: 27444617 PMC: 5081117. DOI: 10.1007/s13311-016-0461-3.

Delayed Administration of WP1066, an STAT3 Inhibitor, Ameliorates Radiation-Induced Lung Injury in Mice.

Yu J, Yuan X, Liu Y, Zhang K, Wang J, Zhang H Lung. 2015; 194(1):67-74.

PMID: 26563331 DOI: 10.1007/s00408-015-9821-8.

Serum Amyloid A as a Biomarker for Radiation Exposure.

Sproull M, Kramp T, Tandle A, Shankavaram U, Camphausen K Radiat Res. 2015; 184(1):14-23.

PMID: 26114330 PMC: 4710171. DOI: 10.1667/RR13927.1.

Protective effect of ulinastatin in patients with non-small cell lung cancer after radiation therapy: a randomized, placebo-controlled study.

Bao P, Zhao W, Li Y, Liu Y, Zhou Y, Liu C Med Oncol. 2014; 32(1):405.

PMID: 25502081 DOI: 10.1007/s12032-014-0405-x.

References

Rube C, Wilfert F, Palm J, Konig J, Burdak-Rothkamm S, Liu L . Irradiation induces a biphasic expression of pro-inflammatory cytokines in the lung. Strahlenther Onkol. 2004; 180(7):442-8. DOI: 10.1007/s00066-004-1265-7. View

Anscher M, Thrasher B, Zgonjanin L, Rabbani Z, Corbley M, Fu K . Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. Int J Radiat Oncol Biol Phys. 2008; 71(3):829-37. DOI: 10.1016/j.ijrobp.2008.02.046. View

Trikha M, Corringham R, Klein B, Rossi J . Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003; 9(13):4653-65. PMC: 2929399. View

Raynes J, Eagling S, McAdam K . Acute-phase protein synthesis in human hepatoma cells: differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin Exp Immunol. 1991; 83(3):488-91. PMC: 1535311. DOI: 10.1111/j.1365-2249.1991.tb05666.x. View

Hodge D, Hurt E, Farrar W . The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005; 41(16):2502-12. DOI: 10.1016/j.ejca.2005.08.016. View

Gao S, Mark K, Leslie K, Pao W, Motoi N, Gerald W . Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 2007; 117(12):3846-56. PMC: 2096430. DOI: 10.1172/JCI31871. View

Rubin P, Johnston C, Williams J, McDonald S, Finkelstein J . A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys. 1995; 33(1):99-109. DOI: 10.1016/0360-3016(95)00095-G. View

Kishimoto T, Akira S, Narazaki M, Taga T . Interleukin-6 family of cytokines and gp130. Blood. 1995; 86(4):1243-54. View

Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M . Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52(3):818-25. DOI: 10.1002/art.20944. View

10.

Chen Y, Hyrien O, Williams J, Okunieff P, Smudzin T, Rubin P . Interleukin (IL)-1A and IL-6: applications to the predictive diagnostic testing of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2005; 62(1):260-6. DOI: 10.1016/j.ijrobp.2005.01.041. View

11.

Mehta V . Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys. 2005; 63(1):5-24. DOI: 10.1016/j.ijrobp.2005.03.047. View

12.

Tsoutsou P, Koukourakis M . Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys. 2006; 66(5):1281-93. DOI: 10.1016/j.ijrobp.2006.08.058. View

13.

Yu T, Whitman G, Thames H, Buzdar A, Strom E, Perkins G . Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst. 2004; 96(22):1676-81. DOI: 10.1093/jnci/djh315. View

14.

Gabay C, Kushner I . Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999; 340(6):448-54. DOI: 10.1056/NEJM199902113400607. View

15.

Brush J, Lipnick S, Phillips T, Sitko J, McDonald J, McBride W . Molecular mechanisms of late normal tissue injury. Semin Radiat Oncol. 2007; 17(2):121-30. DOI: 10.1016/j.semradonc.2006.11.008. View

16.

Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S . Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005; 106(8):2627-32. DOI: 10.1182/blood-2004-12-4602. View

17.

Nishimoto N, Kishimoto T . Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol. 2004; 4(4):386-91. DOI: 10.1016/j.coph.2004.03.005. View

18.

Sharplin J, Franko A . A quantitative histological study of strain-dependent differences in the effects of irradiation on mouse lung during the early phase. Radiat Res. 1989; 119(1):1-14. View

19.

Chen Y, Rubin P, Williams J, Hernady E, Smudzin T, Okunieff P . Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2001; 49(3):641-8. DOI: 10.1016/s0360-3016(00)01445-0. View

20.

Chen Y, Williams J, Ding I, Hernady E, Liu W, Smudzin T . Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol. 2002; 12(1 Suppl 1):26-33. DOI: 10.1053/srao.2002.31360. View